| Expression pattern: |
UP |
| Associated gene: |
PTK6, AGO2 |
| Associated microRNA: |
miR-1324 |
| Biological function: |
Promotes prostate cancer cell proliferation, migration, tumor growth, and enzalutamide resistance; knockdown restrains tumor growth in vivo. |
| Molecular mechanism: |
hsa_circ_0001610 acts as a ceRNA/miRNA sponge for miR-1324, relieving miR-1324-mediated inhibition of PTK6 and increasing PTK6 expression. |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (promotes); migration (promotes); drug resistance (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; RNA-seq; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Western Blot; Bioinformatics Analysis |
| Clinical significance: |
High levels of hsa_circ_0001610 were positively correlated with CRPC and enzalutamide resistance; hsa_circ_0001610 is potentially an effective therapeutic target and specific biomarker for advanced PCa. |
| Description: |
hsa_circ_0001610 is up-regulated in prostate cancer, especially CRPC tissues and cell lines. It promotes PCa proliferation, migration, in vivo tumor growth, and enzalutamide resistance by sponging miR-1324 and upregulating PTK6. The study suggests hsa_circ_0001610 may serve as a therapeutic target and biomarker for advanced PCa. |
| Confidence score: |
0.871 |